Psychotic Disorders
289
30
42
189
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
42 trials with published results (15%)
Research Maturity
189 completed trials (65% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.2%
15 terminated out of 289 trials
92.6%
+6.1% vs benchmark
18%
51 trials in Phase 3/4
22%
42 of 189 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 189 completed trials
Clinical Trials (289)
Brain and Oculometric Markers of Emotional Facial Expression Recognition Deficits
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
Factors of Effectiveness in Italian Forensic Treatment
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
Semantic and Syntactic Computerized Analysis of Free Speech
Evaluation of a Brief Intervention to Improve Engagement in Early Intervention Services for Psychosis
Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
Examining a Digital Health Approach for Advancing Schizophrenia Illness Self-management and Provider Engagement
Transcranial Brain Stimulation and Its Underlying Neural Mechanisms as a Novel Treatment for Auditory Hallucinations
Reconnecting to Ourselves and Others in Virtual Meetings (ROOM)
A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences
The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective.
Impact of VVV Group for Veterans With SMI
Multimodal Physical Exercise Program (Physical Exercise for Psychosis) for People With Psychosis Treated With Long-Acting Injectable Antipsychotics
Testing a Peer-Support Group for Veterans Who Hear Voices
Cannabinoids, Learning, and Memory
Racial Disparities in the Expression of Paranoia
Examining the Efficacy of a Virtual Reality Cognitive Remediation Program for People Living With Psychosis
Effect of Curcumin Add-On Therapy on Quality of Life and IL-1β Levels in Patients With Schizophrenia
Effects of an Acceptance-based Medication Adherence Therapy for Recent-onset Psychosis